Disclosures for "Selective NKCC1 Inhibitors for the Treatment of Neurodevelopmental and Neurological Disorders with Defective NKCC1/KCC2 expression-ratio ")
-
Dr. Savardi has received personal compensation for serving as an employee of Iama Therapeutics. Dr. Savardi has stock in Iama Therapeutics. The institution of Dr. Savardi has received research support from Jerome Lejeune Foundation. Dr. Savardi has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Borgogno has received personal compensation for serving as an employee of IAMA Therapeutics SRL. Dr. Borgogno has stock in IAMA Therapeutics. Dr. Borgogno has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. De Vivo has received personal compensation in the range of $0-$499 for serving as a Consultant for IAMA. Dr. De Vivo has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for PPP. Dr. De Vivo has stock in IAMA. Dr. De Vivo has received intellectual property interests from a discovery or technology relating to health care. Dr. De Vivo has received publishing royalties from a publication relating to health care.
-
Dr. Cancedda has received personal compensation in the range of $0-$499 for serving as a Consultant for IAMA. Dr. Cancedda has stock in IAMA therapeutics. Dr. Cancedda has received intellectual property interests from a discovery or technology relating to health care. Dr. Cancedda has a non-compensated relationship as a Principal investigator with Istituto Italiano di Tecnologia that is relevant to AAN interests or activities.